Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for PCRX

Stock Name	Pacira BioSciences, Inc.
Ticker	PCRX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US6951271005

Show aggregate PCRX holdings

News associated with PCRX

Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages: Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year target price […] - 2025-08-12 04:43:07
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank: Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 20.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,519 shares of the company’s stock after buying an additional 2,848 shares during […] - 2025-08-08 04:56:50
Pacira BioSciences (NASDAQ:PCRX) Upgraded at Truist Financial: Truist Financial upgraded shares of Pacira BioSciences (NASDAQ:PCRX – Free Report) from a hold rating to a buy rating in a research report sent to investors on Friday, MarketBeat.com reports. The brokerage currently has $30.00 target price on the stock. Other equities analysts also recently issued research reports about the stock. HC Wainwright upped their […] - 2025-07-28 04:18:52
Bank of New York Mellon Corp Has $9.60 Million Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX): Bank of New York Mellon Corp decreased its position in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 2.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 386,149 shares of the company’s stock after selling 10,250 shares during the period. Bank […] - 2025-07-22 06:22:51
Louisiana State Employees Retirement System Cuts Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX): Louisiana State Employees Retirement System lessened its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 2.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 21,700 shares of the company’s stock after selling 600 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Pacira […] - 2025-07-21 05:18:53
Illinois Municipal Retirement Fund Has $629,000 Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX): Illinois Municipal Retirement Fund grew its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 24.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,318 shares of the company’s stock after acquiring an additional 5,011 […] - 2025-07-03 05:13:03
Robeco Institutional Asset Management B.V. Purchases 12,750 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX): Robeco Institutional Asset Management B.V. increased its position in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 18.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 82,694 shares of the company’s stock after buying an additional 12,750 shares during the quarter. Robeco […] - 2025-07-02 05:11:08
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of “Hold” by Brokerages: Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report) have been assigned an average rating of “Hold” from the nine research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating […] - 2025-06-18 05:08:55
Head to Head Analysis: Pacira BioSciences (NASDAQ:PCRX) versus I-Mab (NASDAQ:IMAB): Pacira BioSciences (NASDAQ:PCRX – Get Free Report) and I-Mab (NASDAQ:IMAB – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations. Insider and Institutional Ownership 99.7% of Pacira BioSciences […] - 2025-06-18 03:08:45
California State Teachers Retirement System Has $812,000 Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX): California State Teachers Retirement System lessened its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 1.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 43,123 shares of the company’s stock after selling 835 shares during the quarter. California State Teachers […] - 2025-06-11 05:02:51
Friday's ETF with Unusual Volume: XPH: The SPDR S&P Pharmaceuticals ETF is seeing unusually high volume in afternoon trading Friday, with over 318,000 shares traded versus three month average volume of about 57,000. Shares of XPH were up about 1.5% on the day. Components of that ETF with the highest volume on - 2025-06-06 13:49:47
Two Sigma Investments LP Acquires 45,222 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX): Two Sigma Investments LP grew its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 65.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 114,682 shares of the company’s stock after buying an additional 45,222 shares during the quarter. Two Sigma Investments LP’s holdings in Pacira BioSciences were worth […] - 2025-06-02 05:08:57
State of Wyoming Boosts Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX): State of Wyoming lifted its position in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 8.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,566 shares of the company’s stock after purchasing an additional 487 shares during the quarter. State of Wyoming’s holdings […] - 2025-05-27 05:17:01
Graham Capital Management L.P. Sells 61,645 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX): Graham Capital Management L.P. decreased its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 83.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,268 shares of the company’s stock after selling 61,645 shares during the period. Graham Capital Management […] - 2025-05-19 05:27:01
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Voya Investment Management LLC: Voya Investment Management LLC lowered its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 68.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,948 shares of the company’s stock after selling 29,901 shares during the quarter. Voya Investment Management […] - 2025-05-13 05:20:57
MetLife Investment Management LLC Acquires 1,471 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX): MetLife Investment Management LLC grew its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 5.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 27,883 shares of the company’s stock after purchasing an additional 1,471 shares during the quarter. MetLife Investment Management LLC’s holdings in Pacira BioSciences were worth $525,000 as of […] - 2025-05-06 05:01:05
Marshall Wace LLP Has $803,000 Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX): Marshall Wace LLP lessened its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 91.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 42,613 shares of the company’s stock after selling 482,336 shares during the period. Marshall Wace LLP’s holdings in […] - 2025-05-01 04:50:59
Legal & General Group Plc Sells 1,115 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX): Legal & General Group Plc decreased its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 0.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 125,849 shares of the company’s stock after selling 1,115 shares during the period. […] - 2025-04-25 05:08:57
Pacira BioSciences Announces Repurchase Authorization: (RTTNews) - Pacira BioSciences (PCRX) said its Board of Directors has authorized a share repurchase program of up to an aggregate of $300 million with respect to the common stock, replacing the prior authorization. The share repurchase authorization expires at the end of December - 2025-04-18 04:29:04
Sei Investments Co. Has $281,000 Position in Pacira BioSciences, Inc. (NASDAQ:PCRX): Sei Investments Co. trimmed its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 32.6% in the fourth quarter, HoldingsChannel reports. The firm owned 14,927 shares of the company’s stock after selling 7,231 shares during the period. Sei Investments Co.’s holdings in Pacira BioSciences were worth $281,000 as of its most recent SEC filing. […] - 2025-04-11 04:42:54
Wellington Management Group LLP Has $8.86 Million Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX): Wellington Management Group LLP lifted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 3.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 470,191 shares of the company’s stock after purchasing an additional 15,542 shares during the quarter. Wellington Management Group LLP’s holdings in Pacira BioSciences were worth $8,858,000 […] - 2025-04-10 05:29:03
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up on Analyst Upgrade: Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report) gapped up prior to trading on Tuesday after HC Wainwright raised their price target on the stock from $48.00 to $65.00. The stock had previously closed at $22.91, but opened at $27.60. HC Wainwright currently has a buy rating on the stock. Pacira BioSciences shares last traded […] - 2025-04-10 02:24:54
Corebridge Financial Inc. Reduces Position in Pacira BioSciences, Inc. (NASDAQ:PCRX): Corebridge Financial Inc. lowered its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 7.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 24,412 shares of the company’s stock after selling 1,904 shares during the period. Corebridge Financial Inc.’s holdings in Pacira BioSciences were worth $460,000 as of its most recent filing […] - 2025-04-09 05:27:01
Arrowstreet Capital Limited Partnership Sells 505,307 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX): Arrowstreet Capital Limited Partnership cut its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 43.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 647,318 shares of the company’s stock after selling 505,307 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Pacira BioSciences were worth $12,195,000 as of […] - 2025-04-06 05:26:57
Thrivent Financial for Lutherans Has $672,000 Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX): Thrivent Financial for Lutherans reduced its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 1.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 35,689 shares of the company’s stock after selling 534 shares during the period. Thrivent Financial for Lutherans’ holdings […] - 2025-04-03 04:16:46
Prudential Financial Inc. Decreases Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX): Prudential Financial Inc. reduced its position in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 42.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 254,168 shares of the company’s stock after selling 190,286 shares during the period. Prudential Financial Inc.’s holdings in Pacira BioSciences were worth $4,789,000 at the end of the most recent […] - 2025-04-01 05:34:48
Amundi Purchases 15,431 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX): Amundi raised its position in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 200.8% in the 4th quarter, Holdings Channel reports. The firm owned 23,114 shares of the company’s stock after buying an additional 15,431 shares during the period. Amundi’s holdings in Pacira BioSciences were worth $429,000 at the end of the most recent quarter. […] - 2025-03-21 05:59:07
Victory Capital Management Inc. Reduces Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX): Victory Capital Management Inc. trimmed its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 22.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 94,750 shares of the company’s stock after selling 27,478 shares during the quarter. Victory Capital […] - 2025-03-18 05:41:07
Illinois Municipal Retirement Fund Has $383,000 Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX): Illinois Municipal Retirement Fund reduced its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 29.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,307 shares of the company’s stock after selling 8,510 shares during the period. […] - 2025-03-05 08:01:50
Principal Financial Group Inc. Has $4.86 Million Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX): Principal Financial Group Inc. boosted its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 4.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 257,733 shares of the company’s stock after buying an additional 10,306 shares during the quarter. Principal […] - 2025-03-04 06:14:50

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) PCRX holdings

Date	Number of PCRX Shares Held	Base Market Value of PCRX Shares	Local Market Value of PCRX Shares	Change in PCRX Shares Held	Change in PCRX Base Value	Current Price per PCRX Share Held	Previous Price per PCRX Share Held
2026-01-15 (Thursday)	29,498	USD 609,134	USD 609,134	134	USD -43,921	USD 20.65	USD 22.24
2026-01-14 (Wednesday)	29,364	USD 653,055	USD 653,055	134	USD 21,687	USD 22.24	USD 21.6
2026-01-13 (Tuesday)	29,230	USD 631,368	USD 631,368	0	USD -38,876	USD 21.6	USD 22.93
2026-01-12 (Monday)	29,230	USD 670,244	USD 670,244	134	USD -14,385	USD 22.93	USD 23.53
2026-01-09 (Friday)	29,096	USD 684,629	USD 684,629	201	USD -67,219	USD 23.53	USD 26.02
2026-01-08 (Thursday)	28,895	USD 751,848	USD 751,848	0	USD 578	USD 26.02	USD 26
2026-01-07 (Wednesday)	28,895	USD 751,270	USD 751,270	134	USD 23,329	USD 26	USD 25.31
2026-01-06 (Tuesday)	28,761	USD 727,941	USD 727,941	0	USD 6,040	USD 25.31	USD 25.1
2026-01-05 (Monday)	28,761	USD 721,901	USD 721,901	0	USD 18,407	USD 25.1	USD 24.46
2026-01-02 (Friday)	28,761	USD 703,494	USD 703,494	67	USD -39,107	USD 24.46	USD 25.88
2025-12-31 (Wednesday)	28,694	USD 742,601	USD 742,601	0	USD -5,452	USD 25.88	USD 26.07

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of PCRX by Blackrock for IE00BDZVHG35

Show aggregate share trades of PCRX

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2026-01-15 BUY 134 22.555 20.500 20.706 USD 2,775 23.50
2026-01-14 BUY 134 22.530 21.350 21.468 USD 2,877 23.51
2026-01-12 BUY 134 23.850 22.790 22.896 USD 3,068 23.52
2026-01-09 BUY 201 24.749 22.515 22.738 USD 4,570 23.52
2026-01-07 BUY 134 26.480 25.435 25.539 USD 3,422 23.50
2026-01-02 BUY 67 26.810 24.200 24.461 USD 1,639 23.48
2025-12-30 BUY 67 26.200 25.860 25.894 USD 1,735 23.46
2025-12-23 SELL -804 26.330 25.580 25.655 USD -20,627 23.41 Loss of -1,806 on sale
2025-12-19 SELL -3,137 26.990 25.800 25.919 USD -81,308 23.38 Loss of -7,957 on sale
2025-12-17 SELL -375 26.800 25.480 25.612 USD -9,604 23.36 Loss of -846 on sale
2025-12-16 SELL -75 27.160 25.980 26.098 USD -1,957 23.34 Loss of -207 on sale
2025-12-15 BUY 150 27.070 26.100 26.197 USD 3,930 23.33
2025-12-11 BUY 152 26.360 25.222 25.336 USD 3,851 23.30
2025-12-04 BUY 1,480 24.340 23.900 23.944 USD 35,437 23.27
2025-12-02 BUY 1,125 24.325 23.480 23.564 USD 26,510 23.26
2025-11-28 BUY 75 24.500 23.360 23.474 USD 1,761 23.26
2025-11-26 BUY 225 24.180 23.140 23.244 USD 5,230 23.25
2025-11-26 BUY 225 24.180 23.140 23.244 USD 5,230 23.25
2025-11-25 BUY 375 23.970 23.004 23.101 USD 8,663 23.26
2025-11-24 BUY 75 23.470 22.510 22.606 USD 1,695 23.26
2025-11-20 SELL -296 24.950 22.770 22.988 USD -6,804 23.26 Profit of 80 on sale
2025-11-19 BUY 74 24.690 23.760 23.853 USD 1,765 23.25
2025-11-18 BUY 444 24.580 23.620 23.716 USD 10,530 23.25
2025-11-17 BUY 148 24.830 23.630 23.750 USD 3,515 23.24
2025-11-14 BUY 74 23.980 23.260 23.332 USD 1,727 23.24
2025-11-12 BUY 74 24.300 23.850 23.895 USD 1,768 23.24
2025-11-10 BUY 74 23.160 21.675 21.823 USD 1,615 23.23
2025-11-06 BUY 74 21.980 20.640 20.774 USD 1,537 23.25
2025-11-04 BUY 74 22.610 21.200 21.341 USD 1,579 23.26
2025-10-30 BUY 370 21.580 20.700 20.788 USD 7,692 23.29
2025-10-29 BUY 148 21.010 21.460 21.415 USD 3,169 23.30
2025-10-22 SELL -296 21.490 22.060 22.003 USD -6,513 23.35 Profit of 400 on sale
2025-10-20 BUY 148 23.020 23.230 23.209 USD 3,435 23.36
2025-10-17 BUY 370 22.870 22.970 22.960 USD 8,495 23.37
2025-10-15 BUY 592 23.450 23.510 23.504 USD 13,914 23.37
2025-10-03 BUY 518 24.840 25.340 25.290 USD 13,100 23.36
2025-10-02 BUY 74 24.580 25.460 25.372 USD 1,878 23.35
2025-09-30 BUY 148 25.770 25.980 25.959 USD 3,842 23.33
2025-09-26 BUY 148 25.240 25.990 25.915 USD 3,835 23.30
2025-09-25 BUY 148 25.650 26.170 26.118 USD 3,865 23.29
2025-09-18 BUY 80 26.650 26.810 26.794 USD 2,144 23.27
2025-09-17 BUY 240 26.070 26.750 26.682 USD 6,404 23.25
2025-07-17 SELL -160 22.290 22.920 22.857 USD -3,657 23.25 Profit of 63 on sale
2025-07-11 SELL -640 22.900 23.910 23.809 USD -15,238 23.26 Loss of -349 on sale
2025-07-02 BUY 4,400 23.210 23.550 23.516 USD 103,470 23.26
2025-06-25 BUY 160 23.910 24.500 24.441 USD 3,911 23.25
2025-06-20 BUY 1,086 24.230 24.330 24.320 USD 26,412 23.22
2025-06-11 BUY 152 24.340 25.160 25.078 USD 3,812 23.16
2025-06-10 BUY 152 24.870 25.660 25.581 USD 3,888 23.15
2025-06-04 SELL -76 26.980 27.420 27.376 USD -2,081 23.05 Loss of -329 on sale
2025-04-23 BUY 76 25.200 26.650 26.505 USD 2,014 22.21
2025-04-10 SELL -608 23.690 25.560 25.373 USD -15,427 21.95 Loss of -2,082 on sale
2025-04-08 SELL -76 26.270 27.640 27.503 USD -2,090 21.85 Loss of -429 on sale
2025-04-07 SELL -76 22.910 24.170 24.044 USD -1,827 21.84 Loss of -167 on sale
2025-04-04 SELL -380 23.100 24.030 23.937 USD -9,096 21.83 Loss of -802 on sale
2025-04-01 BUY 316 24.070 24.840 24.763 USD 7,825 21.76
2025-03-31 SELL -231 24.850 25.200 25.165 USD -5,813 21.73 Loss of -794 on sale
2025-03-21 BUY 1,059 24.140 24.250 24.239 USD 25,669 21.49
2025-03-14 SELL -1,184 22.870 23.030 23.014 USD -27,249 21.34 Loss of -1,977 on sale
2025-03-07 SELL -146 23.370 24.230 24.144 USD -3,525 21.23 Loss of -426 on sale
2025-03-04 SELL -73 23.530 24.020 23.971 USD -1,750 21.11 Loss of -209 on sale
2025-02-25 BUY 146 25.100 25.580 25.532 USD 3,728 20.81
2025-02-19 SELL -73 26.040 26.890 26.805 USD -1,957 20.46 Loss of -463 on sale
2025-02-13 BUY 219 26.530 27.270 27.196 USD 5,956 20.02
2025-02-12 BUY 73 27.130 27.300 27.283 USD 1,992 19.88
2025-02-11 BUY 292 27.250 27.360 27.349 USD 7,986 19.72
2024-12-30 SELL -2,256 18.940 19.700 19.624 USD -44,272 17.39 Loss of -5,047 on sale
2024-11-18 SELL -1,185 16.640 16.820 16.802 USD -19,910 17.11 Profit of 359 on sale
2024-11-08 SELL -79 17.240 18.340 18.230 USD -1,440 17.12 Loss of -88 on sale
2024-10-21 SELL -80 17.330 17.560 17.537 USD -1,403 0.00 Loss of -1,403 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2026-01-15	BUY	134	22.555	20.500	20.706	USD 2,775	23.50
2026-01-14	BUY	134	22.530	21.350	21.468	USD 2,877	23.51
2026-01-12	BUY	134	23.850	22.790	22.896	USD 3,068	23.52
2026-01-09	BUY	201	24.749	22.515	22.738	USD 4,570	23.52
2026-01-07	BUY	134	26.480	25.435	25.539	USD 3,422	23.50
2026-01-02	BUY	67	26.810	24.200	24.461	USD 1,639	23.48
2025-12-30	BUY	67	26.200	25.860	25.894	USD 1,735	23.46
2025-12-23	SELL	-804	26.330	25.580	25.655	USD -20,627	23.41 Loss of -1,806 on sale
2025-12-19	SELL	-3,137	26.990	25.800	25.919	USD -81,308	23.38 Loss of -7,957 on sale
2025-12-17	SELL	-375	26.800	25.480	25.612	USD -9,604	23.36 Loss of -846 on sale
2025-12-16	SELL	-75	27.160	25.980	26.098	USD -1,957	23.34 Loss of -207 on sale
2025-12-15	BUY	150	27.070	26.100	26.197	USD 3,930	23.33
2025-12-11	BUY	152	26.360	25.222	25.336	USD 3,851	23.30
2025-12-04	BUY	1,480	24.340	23.900	23.944	USD 35,437	23.27
2025-12-02	BUY	1,125	24.325	23.480	23.564	USD 26,510	23.26
2025-11-28	BUY	75	24.500	23.360	23.474	USD 1,761	23.26
2025-11-26	BUY	225	24.180	23.140	23.244	USD 5,230	23.25
2025-11-26	BUY	225	24.180	23.140	23.244	USD 5,230	23.25
2025-11-25	BUY	375	23.970	23.004	23.101	USD 8,663	23.26
2025-11-24	BUY	75	23.470	22.510	22.606	USD 1,695	23.26
2025-11-20	SELL	-296	24.950	22.770	22.988	USD -6,804	23.26 Profit of 80 on sale
2025-11-19	BUY	74	24.690	23.760	23.853	USD 1,765	23.25
2025-11-18	BUY	444	24.580	23.620	23.716	USD 10,530	23.25
2025-11-17	BUY	148	24.830	23.630	23.750	USD 3,515	23.24
2025-11-14	BUY	74	23.980	23.260	23.332	USD 1,727	23.24
2025-11-12	BUY	74	24.300	23.850	23.895	USD 1,768	23.24
2025-11-10	BUY	74	23.160	21.675	21.823	USD 1,615	23.23
2025-11-06	BUY	74	21.980	20.640	20.774	USD 1,537	23.25
2025-11-04	BUY	74	22.610	21.200	21.341	USD 1,579	23.26
2025-10-30	BUY	370	21.580	20.700	20.788	USD 7,692	23.29
2025-10-29	BUY	148	21.010	21.460	21.415	USD 3,169	23.30
2025-10-22	SELL	-296	21.490	22.060	22.003	USD -6,513	23.35 Profit of 400 on sale
2025-10-20	BUY	148	23.020	23.230	23.209	USD 3,435	23.36
2025-10-17	BUY	370	22.870	22.970	22.960	USD 8,495	23.37
2025-10-15	BUY	592	23.450	23.510	23.504	USD 13,914	23.37
2025-10-03	BUY	518	24.840	25.340	25.290	USD 13,100	23.36
2025-10-02	BUY	74	24.580	25.460	25.372	USD 1,878	23.35
2025-09-30	BUY	148	25.770	25.980	25.959	USD 3,842	23.33
2025-09-26	BUY	148	25.240	25.990	25.915	USD 3,835	23.30
2025-09-25	BUY	148	25.650	26.170	26.118	USD 3,865	23.29
2025-09-18	BUY	80	26.650	26.810	26.794	USD 2,144	23.27
2025-09-17	BUY	240	26.070	26.750	26.682	USD 6,404	23.25
2025-07-17	SELL	-160	22.290	22.920	22.857	USD -3,657	23.25 Profit of 63 on sale
2025-07-11	SELL	-640	22.900	23.910	23.809	USD -15,238	23.26 Loss of -349 on sale
2025-07-02	BUY	4,400	23.210	23.550	23.516	USD 103,470	23.26
2025-06-25	BUY	160	23.910	24.500	24.441	USD 3,911	23.25
2025-06-20	BUY	1,086	24.230	24.330	24.320	USD 26,412	23.22
2025-06-11	BUY	152	24.340	25.160	25.078	USD 3,812	23.16
2025-06-10	BUY	152	24.870	25.660	25.581	USD 3,888	23.15
2025-06-04	SELL	-76	26.980	27.420	27.376	USD -2,081	23.05 Loss of -329 on sale
2025-04-23	BUY	76	25.200	26.650	26.505	USD 2,014	22.21
2025-04-10	SELL	-608	23.690	25.560	25.373	USD -15,427	21.95 Loss of -2,082 on sale
2025-04-08	SELL	-76	26.270	27.640	27.503	USD -2,090	21.85 Loss of -429 on sale
2025-04-07	SELL	-76	22.910	24.170	24.044	USD -1,827	21.84 Loss of -167 on sale
2025-04-04	SELL	-380	23.100	24.030	23.937	USD -9,096	21.83 Loss of -802 on sale
2025-04-01	BUY	316	24.070	24.840	24.763	USD 7,825	21.76
2025-03-31	SELL	-231	24.850	25.200	25.165	USD -5,813	21.73 Loss of -794 on sale
2025-03-21	BUY	1,059	24.140	24.250	24.239	USD 25,669	21.49
2025-03-14	SELL	-1,184	22.870	23.030	23.014	USD -27,249	21.34 Loss of -1,977 on sale
2025-03-07	SELL	-146	23.370	24.230	24.144	USD -3,525	21.23 Loss of -426 on sale
2025-03-04	SELL	-73	23.530	24.020	23.971	USD -1,750	21.11 Loss of -209 on sale
2025-02-25	BUY	146	25.100	25.580	25.532	USD 3,728	20.81
2025-02-19	SELL	-73	26.040	26.890	26.805	USD -1,957	20.46 Loss of -463 on sale
2025-02-13	BUY	219	26.530	27.270	27.196	USD 5,956	20.02
2025-02-12	BUY	73	27.130	27.300	27.283	USD 1,992	19.88
2025-02-11	BUY	292	27.250	27.360	27.349	USD 7,986	19.72
2024-12-30	SELL	-2,256	18.940	19.700	19.624	USD -44,272	17.39 Loss of -5,047 on sale
2024-11-18	SELL	-1,185	16.640	16.820	16.802	USD -19,910	17.11 Profit of 359 on sale
2024-11-08	SELL	-79	17.240	18.340	18.230	USD -1,440	17.12 Loss of -88 on sale
2024-10-21	SELL	-80	17.330	17.560	17.537	USD -1,403	0.00 Loss of -1,403 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of PCRX

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	52,099	0	123,269	42.3%
2025-09-18	43,539	0	107,413	40.5%
2025-09-17	54,189	0	246,306	22.0%
2025-09-16	82,421	0	239,735	34.4%
2025-09-15	159,073	2	307,671	51.7%
2025-09-12	205,225	0	267,650	76.7%
2025-09-11	80,513	0	176,033	45.7%
2025-09-10	116,502	0	171,706	67.8%
2025-09-09	112,414	0	188,831	59.5%
2025-09-08	105,261	0	236,751	44.5%
2025-09-05	75,537	0	131,849	57.3%
2025-09-04	149,745	7,159	289,312	51.8%
2025-09-03	97,245	0	200,543	48.5%
2025-09-02	75,560	0	288,063	26.2%
2025-08-29	110,380	0	181,051	61.0%
2025-08-28	205,314	2,000	326,738	62.8%
2025-08-27	195,950	0	334,509	58.6%
2025-08-26	80,181	0	135,869	59.0%
2025-08-25	65,949	0	124,996	52.8%
2025-08-22	49,762	0	102,734	48.4%
2025-08-21	80,876	0	126,100	64.1%
2025-08-20	56,330	0	101,290	55.6%
2025-08-19	75,737	0	218,361	34.7%
2025-08-18	152,697	0	401,062	38.1%
2025-08-15	125,600	0	367,483	34.2%
2025-08-14	93,376	0	314,283	29.7%
2025-08-13	66,587	0	288,603	23.1%
2025-08-12	131,601	17	215,996	60.9%
2025-08-11	87,101	0	177,377	49.1%
2025-08-08	318,236	0	459,607	69.2%
2025-08-07	223,165	0	394,083	56.6%
2025-08-06	500,520	0	674,653	74.2%
2025-08-05	136,316	0	282,392	48.3%
2025-08-04	240,686	0	344,051	70.0%
2025-08-01	450,666	0	517,524	87.1%
2025-07-31	124,402	0	322,818	38.5%
2025-07-30	121,888	0	287,261	42.4%
2025-07-29	44,574	0	85,432	52.2%
2025-07-28	84,917	0	184,799	46.0%
2025-07-25	137,007	43	238,974	57.3%
2025-07-24	47,747	0	98,609	48.4%
2025-07-23	48,178	0	113,468	42.5%
2025-07-22	66,252	2,839	149,873	44.2%
2025-07-21	111,788	0	294,458	38.0%
2025-07-18	99,442	795	177,714	56.0%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE